Livagen
Not FDA approvedSynthetic short peptide bioregulator
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Animal / preclinical only. Evidence is largely animal or in-vitro
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Livagen is a synthetic tetrapeptide (usually described as Lys-Glu-Asp-Ala) developed in Russia as part of the Khavinson group of so-called peptide bioregulators. It is proposed to influence gene expression and chromatin structure, particularly in liver and immune cells, but this mechanism is not well established.
What the evidence shows
There are no registered human clinical trials, and the roughly 18 published papers are mostly cell and animal studies from a small group of researchers. Any benefit in humans is unproven, and its effects and safety in people remain unclear.
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Effects of Livagen peptide on chromatin activation in lymphocytes from old people.
Tissue-specific effects of peptides.
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.
Effects of short peptides on lymphocyte chromatin in senile subjects.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.